Status:
COMPLETED
Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty
Lead Sponsor:
Danderyd Hospital
Collaborating Sponsors:
Sanofi
Conditions:
Bone Loss
Eligibility:
All Genders
40-70 years
Phase:
PHASE4
Brief Summary
Can risedronate given once weekly for 6 months prevent periprosthetic bone loss after uncemented total hip arthroplasty?
Detailed Description
Periprosthetic bone loss after total hip arthroplasty is the main factor in limiting the longevity of implants used for treatment of osteoarthritis. Bone loss leads to implant destabilization. Bisphos...
Eligibility Criteria
Inclusion
- Patients on the waiting list for a total hip arthroplasty
- Primary osteoarthritis
- Osteoarthritis secondary to congenital dislocation of the hip
Exclusion
- Rheumatoid arthritis
- Bisphosphonate treatment
- Osteomalacia
- Hypocalcemia
- Previous surgery of the affected hip
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT00772395
Start Date
April 1 2006
End Date
February 1 2013
Last Update
September 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Orthopaedic department, Danderyd Hospital
Stockholm, Stockholm County, Sweden, 18288